At a glance
- Originator Kaneka
- Developer Kanegafuchi Chemicals; Kaneka
- Class Antihyperlipidaemics; Antineoplastics; Nootropics
- Mechanism of Action Protein tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Atherosclerosis; Coronary artery restenosis